Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinomaChristoph Seidel, Viktor Grünwald, Jonas Busch et al.|European Journal of Cancer|2012Cited by 54
Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinomaJonas Busch, Viktor Grünwald, Christoph Seidel et al.|BMC Cancer|2011Cited by 54
Sequence Therapy in Patients with Metastatic Renal Cell Carcinoma: Comparison of Common Targeted Treatment Options Following Failure of Receptor Tyrosine Kinase InhibitorsJonas Busch, Steffen Weikert, Christoph Seidel et al.|European Urology|2011Cited by 45
Efficacy of Sunitinib Re-Exposure after Failure of an mTOR Inhibitor in Patients with Metastatic RCCViktor Grünwald, Manfred Johannsen, Steffen Weikert et al.|Onkologie|2011Cited by 42
Retrospective Comparison of Triple-sequence Therapies in Metastatic Renal Cell CarcinomaJonas Busch, Steffen Weikert, Christoph Seidel et al.|European Urology|2012Cited by 25